Mixed treatment comparison (MTC) is a generalisation of meta-analysis. Instead of the same treatment for a disease being tested in a number of studies, a number of different interventions are considered. Meta-regression is also a generalisation of meta-analysis where an attempt is made to explain the heterogeneity between the treatment effects in the studies by regressing on study-level covariables. Our focus is where there are several different treatments considered in a number of randomized controlled trials in a specific disease, the same treatment can be applied in several arms within a study, and where differences in efficacy can be explained by differences in the study settings. We develop methods for simultaneously comparing several treatments and adjusting for study level covariables by combining ideas from MTC and meta-regression.
Introduction
We use a case study from rheumatoid arthritis (RA). The discovery that the inhibition of Tumor Necrosis Factor alpha (TNF-∝) and Interleukin 1 (IL-1) may reduce the manifestations of RA, improving function and retarding radiological progression has led to the development of novel treatments (1) . We refer to these treatments as biologics. Previously the early initiation of disease modifying anti-rheumatic drugs (DMARDs) like the antimetabolite methotrexate (MTX), were considered the most successful strategy for delaying the progression in this chronic inflammatory disease (2) . We study the currently licensed treatments, the TNF-∝ antagonists adalimumab (Humira), infliximab (Remicade) and etanercept (Enbrel) along with the IL-1 inhibitor anakinra (Kineret). A number of systematic reviews of these biologic therapies have confirmed their safety and efficacy in placebo controlled trials (3) (4) (5) (6) (7) (8) . Efficacy in RA trials is determined using the American College of Rheumatology (ACR) improvement criteria, a measure which combines a core set of disease activity measures. An ACR50 requires a 50% reduction in the tender joint count, a 50% reduction in the swollen joint count, and a 50% reduction in 3 of 5 additional measures including patient global assessment, physician global assessment, pain, disability and an acute-phase reactant (9) . However, most trials have been performed on relatively small and diverse patient populations.
Meta-analysis attempts to combine the results from a number of studies that address a set of related research hypotheses. These studies may have been performed amongst different patient groups and with methodological differences, so heterogeneity between trials is expected with the true effects in each study not being identical. In a random-effects meta-analysis a random-effects distribution is placed on these effects sizes, and the mean used as the estimate of the overall mean.
Mixed treatment comparison evidence synthesis is an extension of meta-analysis (10) . Instead of all studies comparing the same treatment with the same comparator, different comparisons are made. Mixed treatment comparisons enable estimates of intervention effects to be estimated that are not directly observed, or observed intervention effect estimates to be strengthened from indirect estimates. For example, no head-to-head study of etanercept and infliximab exists, but this could be estimated from studies comparing etanercept versus placebo and studies comparing infliximab versus placebo. We are concerned with a connected network of randomized controlled trials (11) , where several studies consider a collection of new interventions. Two deviations from a standard mixed treatment comparison are found in this study. Firstly, MTX is sometimes used in both the placebo arm and in combination with a biologic in the treatment arm, sometimes it is only used in the control arm, and sometimes it is not used at all. Secondly multiple treatment arms of the same drug are used in each of the studies, each using different doses and / or timing regimes.
Meta-regression attempts to explain the difference between intervention effects in a collection of studies (12) . Figure 1 shows how the average disease duration of the patients in the studies relates to the log odds ratio of an ACR50 event. A weighted linear regression is fitted to this relationship. While this has many shortfalls; it ignores the heterogeneity between the studies and all the mixed treatment comparison features described above, it does demonstrate the clear relationship between disease duration and the relative effectiveness of biologic treatments versus control.
Meta-regression attempts to explain the difference in log odds ACR50 response between studies by regressing this effect sizes from each study onto the disease duration for each study. The effect sizes, adjusted for study level characteristics, will 4 not be identical, as the regression will not completely explain the heterogeneity, so a random-effects distribution is placed on the adjusted effects sizes.
A previous meta-analysis compared the three therapies that target TNF-∝ (6).
However this focussed on trials which were of a more similar design. Since then, the number of studies has doubled, and includes many in patient populations with early disease where the efficacy of the comparator arm is relatively high.
The objective of this paper is to combine standard meta-regression techniques and ideas from mixed treatment comparisons to perform indirect comparisons. The case study aims to find the odds ratio of an ACR50 event at six months if treated with a biologic in comparison to control. We examine how the odds ratio for the relative effectiveness of biologic therapy versus control varies with different important study level covariates and compare the odds ratios for the four licensed biologic treatments. submissions.
Methods

Literature search and data extraction
The initial screen of the search results identified 107 reports which were potentially relevant. When we applied the filter that studies had to be randomised controlled trials comparing biologic agents to a placebo in patients with RA, only 60 reports remained. We applied a secondary filter to remove trials with a horizon less than 6 months (the point when the full potential of biologic therapy is generally reached), trials which did not report the primary measure of synthesis (the ACR response criteria) and trials that did not use a conventional comparison to methotrexate or placebo.
Thirteen RCTs (27 individual reports) were included in the final analysis. Data are given in Table 1 . Four of these studied adalimumab (13) (14) (15) (16) , three studied anakinra (17) (18) (19) , four studied etanercept (20) (21) (22) (23) , and two studied infliximab (24;25) . The average baseline disease duration varied from between one and 14 years and mean baseline Health Assessment Questionnaire Disability Index (HAQ-DI, the primary measure of disability in patients with RA) ranged from 1.3 to 1.9.
Model development
When a binary outcome is being explored in a meta-regression is it best to use the raw outcome counts as this avoids using an estimated standard error of the log odds ratio (12) . There are many possible study and patient level covariates that could be used to explain the heterogeneity. With relatively few studies, multiple analyses using all study level covariables will have a high probability of finding a spurious explanatory variable. Further there are insufficient degrees of freedom to sensibly model many covariables. We chose two covariables, disease duration (mean years), (26) and baseline HAQ-DI (a measure of disability) (27) , which were measured in all identified trials and are known to have prognostic value in determining the effect of treatment.
The studies used in the meta-regression are all randomised controlled trials.
However, the meta-regression finds a relationship between the log odds ratio of the ACR50 outcome and study level characteristics, but these study level characteristics have not been randomised, so the regression can be regarded as an observational relationship. Two of the studies (ASPIRE 2004(24) and PREMIER 2005(13)) have missing data for the six month ACR measure. These studies are in patients with newly diagnosed RA, which may be systematically different from trials in patients with established disease. This lack of 6 month ACR50 data could lead to biased estimated treatment effects for infliximab and adalimumab. Even though metaregression, adjusting for disease duration, may go some way to redress this bias, it is unrealistic to suppose that it would fully adjust the analysis. To deal with this we have assumed that the missing six-month ACR50 outcomes can be estimated by the 12-months ACR50 outcomes available in these two studies.
For the statistical modelling, our notation is as follows: i =1…13 denotes the study index; j=0…J i the arm within the study, where 0 indexes the control group and J i is the number of treatment regimes being tested in study i; denotes the biologic agent used in study 
We assume each of these log odds ratios for biologic treatments have been sampled from a normal distribution. This is assuming all the treatment effects are exchangeable both between studies and within studies.
σ is the heterogeneity between treatments, assumed common for all treatments, and k µ the overall log odds ratio of ACR50 given treatment with a biologic k. This is assuming all the treatment effects are exchangeable between treatment arms. We also assume equal heterogeneities between arms for treatment with every biologic agent. The model also allows for multiple treatment arms of the same drug within a study.
Model 2 -Mixed treatment comparison model with univariate random effects, including meta-regression coefficients
The average baseline disease duration and average baseline HAQ of patients are study level characteristics. In our second model, they are included as treatment-disease duration and treatment-HAQ interaction effects to assess how they affect the log odds of ACR50 if treated compared to control. This is written:
This assumes that the β and γ parameters are the same for all treatments. In Model 2 therefore, the ij θ have now been adjusted for study level covariates. Thus the ij θ are interpreted as the log odds ratio for the relevant biologic therapy at the mean value of the study level covariates.
Model 3 -Mixed treatment comparison with bivariate random effects
The exchangeability assumption used on the random effects in model 1 and 2 is strong -the treatment effects both within a study and between studies are all exchangeable with each other. A further weakness is the effect of MTX is assumed to be the same in each study and it would be better to treat this in a similar way to treatment with a biologic, and allow these to be exchangeable between studies. This is written
We assume each of these log odds ratios has been sampled from a bivariate normal normal distribution. This is assuming all the treatment effects are exchangeable between studies. We also assume equal heterogeneities between studies for treatment with every biologic agent, treatment with MTX and the comparison between the two.
σ is the heterogeneity between studies, and β µ and i k µ the overall log odds ratio of ACR50 given treatment with MTX and biologic k respectively.
The model also allows for multiple treatment arms of the same drug within a study, and assumes that treatment effects are the same for each arm within a study where the same treatment is used.
Model 4 -Mixed treatment comparison with bivariate random effects, including meta-regression coefficients 7
The average baseline disease duration and average baseline HAQ of patients are included in model 4 as meta-regression covariables in the same way as in model 2,
and with the same random-effects structure as model 3: The code used to fit model 4 is given in the Appendix.
Results
The results of fitting the range of different models are shown in Table 2 . This gives the median and the standard deviation of the posterior distribution of parameters, along with 95% credible intervals. There is very little difference in the inference from the meta-regression models 2 and 4, and we consider the assumption of study exchangeability of treatment effects of both biologic and MTX treatment, and common effects within studies to be a better assumption than between arm exchangeability on only the effect of biologics, which largely ignores the nested structure of the data. From now on we concern ourselves with describing the results from model 4. is of a comparable order to the 0.112 gradient estimate from the linear regression (weighted by the variance of the log odds ratio) in Figure 1 , which shows a plot of the observed log odds ratio of ACR50 at six months for all treatments plotted against the average disease duration for each study The HAQ parameter is estimated to be - 
Discussion
This is the first study, of which we are aware, to combine techniques of mixed treatment comparisons with meta-regression to adjust for study level covariables.
Our case study, an important topic in the choice of treatments in Rheumatoid Arthritis, examined 13 randomised controlled trials that tested biologic treatments against comparator. No head to head studies of these therapies have been performed. Each of the trials measured ACR50 as an outcome and may have used the active comparator MTX in the control arm and in combination with the biologic therapy in the treatment arm. Additionally, the differences in study inclusion criteria meant disparity in the patient populations between the trials. Also these trials may have incorporated several treatment arms. We developed methods to deal with all these features. First, we used the techniques of mixed treatment comparisons by allowing different random effects for each biologic treatment in model 1 (where exchangeability is assumed between treatment arms), and also for treatment with MTX in model 3 (where exchangeability is assumed between studies). Second, ideas from meta-regression introduced study level covariables into models 2 and 4.
In terms of the specific case study, the results confirm the efficacy of TNF-∝ antagonists over control even for patients with very early disease. While each TNF-∝ antagonist has a slightly different mode of action or formulation, we found no statistical difference between their ability to induce an ACR50 response over placebo. We found that the expected effect of IL-1 antagonist anakinra is also superior to control for patients with disease duration greater than 6 years. However, less data are available for the anakinra estimate compared to TNF-∝ antagonist combined estimate so this leads to comparatively wider CI. This penalises anakinra, as longer disease duration is then necessary for the CI of the estimated effectiveness to exclude zero.
There are a number of potential limitations to the study. Models 1 and 2 assumed exchangeability between treatment arms (both within a study and between studies), and models 3 and 4 assumed exchangeability between studies. Models 3 and 4 also assume that the treatment effects are the same for each arm within a study where a particular treatment is used. This is reasonable for MTX, as the same dose is always used, however each arm of a study may use a different dose of the biologic drug.
The model could be improved if some dose-response relationship were to be included in the model, but it is not clear how say 25mg of etanercept could be compared with 20mg of Adalimumab, nor even how 20mg of adalimumab administered every week should be compared with 40mg every other week. We do not explicitly account for the dose used within a treatment arm, but could extend model 4 to acknowledge that the treatment effects could be different for each arm, and make an exchangeability assumption on these within a study. The study level treatment effects are then also assumed to be exchangeable between studies. 
2 w σ is the heterogeneity within studies and the heterogeneity between studies.
The meta-regression element of the model explains the between study heterogeneity and should reduce this, but does not affect the within study heterogeneity. However, we feel this model is allowing too much variability in the model, and an explicit dose response relationship would be better than the within study exchangeability assumption.
σ
Secondly, we estimated β and β µ from studies where MTX is used in the control but not in the intervention arm. Estimates of these parameters could have been improved by including trials of MTX vs. placebo, as these would have given a direct estimate of these parameters. We decided to restrict the meta-analysis to studies for biologic treatment, as most trials of MTX date back to an era before ACR50 measurement became the norm. We were also aware that the populations studied in these trials were often substantially different from the populations in our 13 studies.
Thirdly, an assumption of the models is that the study level parameters γ are the same for all treatments. This is probably a reasonable assumption for the TNF antagonists as they all have a similar mechanism of action, but maybe less reasonable for anakinra.
Fourthly, the relationship of six-month ACR50 with mean disease duration or with mean baseline HAQ of patients across trials may not be the same as these relationships for individual patients within trials (12) . The relationship demonstrated here between the patient characteristics might be due to confounding with other study level variables that may not even have been measured, and there may or may not be a relationship between six-month ACR50 and disease duration or HAQ at a patient level. This is a generic problem with meta-regression and individual patient data is needed to find a relationship at this level. However, other studies have shown that disease duration and baseline HAQ are strong predictors of efficacy (26;27).
Lastly, we were not able to address the concern of publication bias, which could lead to a spuriously elevated risk estimate. This could potentially be relevant for anakinra, which has not reported the ACR results from its largest randomised study (31) . The models defined in this paper differ from those of Lu and Ades in a number of ways. The context of our RA example was that there were several treatment arms within a study all applying that same treatment. The control arm may be a placebo or 13 14 an active comparator, and the active comparator may also be used in combination with treatment, but possibly not for all treatment arms. Lu and Ades did not need to employ methods to account for these trial features. Furthermore, our methods also include meta-regression techniques so study level variables are used to try and explain the variability between studies, and the different doses between arms in a study are modelled.
An advantage with using MCMC to fit these models it that it allows credible interval to be sampled directly for statistics of interest, for example, the log odds ratio for a given disease duration and the difference between log odds ratios for different treatments. In this way all the correlations betweens the parameters that make up these statistics are dealt with appropriately. The models could have been fitted using classical techniques, although they may not fit into the pre-programmed routines of a package.
Until this analysis, it had been impossible to determine whether one TNF antagonist is superior to another. A direct randomised head to head study in the future is unlikely as there is no incentive for the existing pharmaceutical companies to fund such a study, and it would be difficult for a public body to justify the expense such a trial would consume. With the current evidence, we found no evidence to suspect that there are material differences between TNF-∝antagonists and on this evidence, claims that there are differences in efficacy must be considered with caution. There has been no formal analysis as yet of the value of information which might be provided from a head to head trial and given the analysis presented here, such a trial may not be the highest priority for further research. This does not mean that no further research is required. Sequential use of the TNF-∝therapies is becoming more common and long-term effectiveness and safety is being monitored by a number of registry studies.
In conclusion, this paper defines a methodology for combining meta-regression techniques with ideas from mixed treatment comparisons. This allows different treatments for the same condition to be compared whilst adjusting for difference in the study populations.
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Appendix
Bugs data set
list( N.c=13, study.c=c (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13) , mtx.c=c (1, 0, 1, 0, 1, 1, 1, 1, 1, 1, 1, 0, 1) , n.c=c (74, 121, 251, 80, 30, 217, 228, 88, 282, 62, 200, 110, 257) , r.acr.c=c (3, 10, 20, 4, 1, 67, 91, 8, 91, 5, 19, 9, 118) , N.t=33, study.t=c (1, 1, 1, 1, 1, 2, 2, 2, 3 , 4, 4, 5, 6, 6, 7, 7, 8, 8, 8, 8, 9, 9, 10, 10, 10, 11, 11, 12, 12, 12, 12, 13, 13) , mtx.t=c (1, 1, 1, 1, 1, 0, 0, 0, 1, 0, 0, 1, 0, 0, 1, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1 Tables and figures   Table 1 Data extracted from included phase three studies Table 2 Parameter estimates for models 1 to 5. Figure 1 Observed log odds ratio of ACR50 at six months in all treatment arms of studies compared to the control arm, by average disease duration. The linear regression weighted by the inverse of the variance of the log odds ratio estimate is also shown. The area of each circle is inversely proportional to the variance of the log odds ratio estimate and the shading of the circle relates to the treatment used. The disease duration is the same for all arms within a study, and the study relating to the "column" of disease duration circles is given in the margin above the plot. 23
